---
title: "Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285305447.md"
description: "Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News"
datetime: "2026-05-05T19:35:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285305447.md)
  - [en](https://longbridge.com/en/news/285305447.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285305447.md)
---

# Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News

Avalo Therapeutics Announces Pricing of $375 Million Public Offering | AVTX Stock News

### Related Stocks

- [AVTX.US](https://longbridge.com/en/quote/AVTX.US.md)
- [BMED.US](https://longbridge.com/en/quote/BMED.US.md)
- [TMED.US](https://longbridge.com/en/quote/TMED.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty](https://longbridge.com/en/news/286366040.md)
- [These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results](https://longbridge.com/en/news/286424446.md)
- [Avalo Therapeutics Q1 net loss widens on increased R&D spend](https://longbridge.com/en/news/286249018.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)